June 20-23 2025

Dr Karim Bouzakri, our laboratory director, and Dr Allan Langlois, associate lab director, were in Chicago for one of the world's largest diabetes congress organized by the American Diabetes Association (ADA).

At this occasion, Dr Allan Langlois presented our project, which focuses on islet transplantation and a promising therapeutic approach for people with unstable T1DM:

ILV-001, a Myokine of Interest to Potentiate the Success of Pancreatic Islet Transplantation and Treat a Maximum Number of People with T1DM

The main challenge is to reduce the number of pancreases needed to treat a single person. In this context, we have recently demonstrated that ILV-001, a component of the muscle secretome, enables rapid uptake and lasting function of the graft. The aim of the project was to determine whether ILV-001 could reduce the pancreatic islets quantity to be transplanted in order to normalize glycemia. To this end, we have injected 5000 IEQ/kg untreated (control group) or pre-treated with 1µg/ml ILV-001in the liver of diabetic syngeneic rats via the portal vein. Either transplanted animals received or not a daily intraperitoneal injection of ILV-001. A metabolic follow up was performed for 3 months (Weight gain, glycemia, c-peptidemia, graft function). Interestingly, we demonstrated that whatever ILV-001 administration modality, our myokine potentiates effectiveness of islet transplantation and allows to reduce by at least half the number of islets needed to normalize glycemic control in diabetic rats.



CeeD was at the previous American Diabetes Association (ADA) scientific sessions: